News for Ono Pharmaceutical Co., Ltd. (OPHLF)

Summary Vertex Pharmaceuticals Inc (VRTX) has entered into an exclusive collaboration and license agreement with Ono Pharmaceutical Co., Ltd. to develop and com

[url="]Vertex Pharmaceuticals Incorporated[/url] (Nasdaq: VRTX) and [url="]Ono Pharmaceutical Co., Ltd.[/url] (OTCMKTS: OPHLY) today announced an exclusive col

Vertex Pharmaceuticals (VRTX) and Ono Pharmaceutical (OPHLY) forge an exclusive agreement for povetacicept in Japan and South Korea. Ono will handle mar

Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral Presentat

The following slide deck was published by Ono Pharmaceutical Co., Ltd.

Ono Partnering with LabCentral and MBC BioLabs for Fifth Consecutive Year

[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a licen

**media[558446]**

- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC

**media[552869]**

[url="]Pfizer Inc.[/url] (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart Month was officially declared by President Lyndon B.

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (m

OSAKA, Japan and MONTREAL , Dec. 6, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; 'Ono') announced that it has entered into a drug discovery collaboration agreement with Congruence Therapeutics (Headquarters: Montreal, Quebec, Canada; CEO: Clarissa Desjardins; 'Congruence') to generate novel small molecule correctors against multiple protein targets in the oncology area by leveraging Congruence's proprietary drug discovery platform, Revenir™.

November 14, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to investing platform covering biotech and medical technology sto...

Equillium shares downgraded to hold from buy

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Kinaxis provides end-to-end supply chain orchestration platform to support Ono Pharmaceutical’s further global growth Kinaxis provides end-to-end supply chain orch…

– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic...